BR112022003474A2 - Vacinas do vírus da hepatite b - Google Patents
Vacinas do vírus da hepatite bInfo
- Publication number
- BR112022003474A2 BR112022003474A2 BR112022003474A BR112022003474A BR112022003474A2 BR 112022003474 A2 BR112022003474 A2 BR 112022003474A2 BR 112022003474 A BR112022003474 A BR 112022003474A BR 112022003474 A BR112022003474 A BR 112022003474A BR 112022003474 A2 BR112022003474 A2 BR 112022003474A2
- Authority
- BR
- Brazil
- Prior art keywords
- hbv
- vaccines
- hepatitis
- polypeptides
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893546P | 2019-08-29 | 2019-08-29 | |
| US201962941125P | 2019-11-27 | 2019-11-27 | |
| PCT/US2020/048411 WO2021045969A1 (en) | 2019-08-29 | 2020-08-28 | Hepatitis b virus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022003474A2 true BR112022003474A2 (pt) | 2022-05-24 |
Family
ID=74096044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022003474A BR112022003474A2 (pt) | 2019-08-29 | 2020-08-28 | Vacinas do vírus da hepatite b |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12485168B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4021923A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7635208B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220090497A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114729010B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020342385A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022003474A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3149415A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290924A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022002270A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12022550490A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021045969A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20241379T1 (hr) | 2019-09-30 | 2024-12-20 | Gilead Sciences, Inc. | Cjepiva za hbv i postupci za liječenje hbv |
| WO2023085956A1 (en) * | 2021-11-09 | 2023-05-19 | Avalia Immunotherapies Limited | Novel therapeutic vaccines |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL86832A (en) | 1987-06-22 | 2002-09-12 | Medeva Holdings Bv | A recombinant DNA molecule containing a nucleotide sequence of part of the region encoding HBV pre-1s, an immunogenic particle containing multiple peptide monomers containing a pre-s1 epitope and pharmaceutical preparations containing it |
| DE19904800C1 (de) | 1999-02-05 | 2001-02-08 | Eberhard Hildt | Partikel zur Gentherapie |
| WO2001027281A1 (en) | 1999-10-08 | 2001-04-19 | Celltech Pharma Europe Limited | Designing immunogens |
| ATE320493T1 (de) | 2000-06-22 | 2006-04-15 | Ucb Pharma Ltd | Modifizierung des hepatitis b kernantigens |
| EP1390397B1 (en) | 2001-05-25 | 2008-10-01 | Dobeel Corp. | Pre-s protein of hepatitis b virus (hbv) as an adjuvant and a component of hbv vaccine |
| US8278432B2 (en) | 2002-03-29 | 2012-10-02 | Innogenetics N.V. | HBV drug resistance methods |
| KR101326612B1 (ko) | 2003-10-21 | 2013-11-12 | 멜버른 헬스 | Ｈｂｖ 변이체 검출 및 응용 |
| AU2005285513B2 (en) | 2004-05-25 | 2011-02-24 | Oregon Health And Science University | SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors |
| EP2029747A4 (en) | 2006-06-06 | 2011-01-05 | Melbourne Health | PROOF AND USE OF ANTIVIRAL RESISTANCE MUTATIONS |
| US20080171062A1 (en) * | 2006-08-16 | 2008-07-17 | Monica Sala-Schaeffer | Recombinant HBsAg virus-like particles containing polyepitopes of interest, their production and use |
| CA2770075C (en) * | 2009-08-07 | 2021-08-24 | Perrine Martin | Composition for treating hbv infection |
| WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| PT3351636T (pt) | 2010-05-14 | 2020-09-24 | Univ Oregon Health & Science | Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos |
| PE20140844A1 (es) | 2011-02-12 | 2014-07-14 | Globeimmune Inc | Terapeuticos a base de levadura para infeccion de la hepatitis b cronica |
| ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
| KR101418836B1 (ko) | 2012-04-05 | 2014-08-13 | 서울대학교산학협력단 | 간질환 진단용 마커 및 이의 용도 |
| US8852745B2 (en) | 2012-10-12 | 2014-10-07 | Hoya Corporation | Optical glass, press-molding glass material, optical element and method of manufacturing the same, and bonded optical element |
| GB201223386D0 (en) * | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| LT2964769T (lt) | 2013-03-05 | 2018-12-10 | Oregon Health & Science University | Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| EA201791806A1 (ru) | 2015-02-10 | 2017-12-29 | Орегон Хелс Энд Сайенс Юниверсити | Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов |
| EP3402888B1 (en) | 2016-01-12 | 2020-08-26 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Means and methods for treating hbv |
| WO2018075591A1 (en) * | 2016-10-18 | 2018-04-26 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
| GB201705765D0 (en) | 2017-04-10 | 2017-05-24 | Univ Oxford Innovation Ltd | HBV vaccine |
| CN113950334B (zh) * | 2019-06-07 | 2025-01-28 | 俄勒冈健康与科学大学 | 乙型肝炎病毒特异性t细胞应答 |
-
2020
- 2020-08-28 BR BR112022003474A patent/BR112022003474A2/pt not_active IP Right Cessation
- 2020-08-28 US US17/638,344 patent/US12485168B2/en active Active
- 2020-08-28 CN CN202080061230.2A patent/CN114729010B/zh active Active
- 2020-08-28 MX MX2022002270A patent/MX2022002270A/es unknown
- 2020-08-28 EP EP20830016.0A patent/EP4021923A1/en active Pending
- 2020-08-28 KR KR1020227009774A patent/KR20220090497A/ko not_active Ceased
- 2020-08-28 JP JP2022513077A patent/JP7635208B2/ja active Active
- 2020-08-28 PH PH1/2022/550490A patent/PH12022550490A1/en unknown
- 2020-08-28 AU AU2020342385A patent/AU2020342385A1/en not_active Abandoned
- 2020-08-28 CA CA3149415A patent/CA3149415A1/en active Pending
- 2020-08-28 WO PCT/US2020/048411 patent/WO2021045969A1/en not_active Ceased
-
2022
- 2022-02-27 IL IL290924A patent/IL290924A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020342385A1 (en) | 2022-03-31 |
| US12485168B2 (en) | 2025-12-02 |
| JP2022545530A (ja) | 2022-10-27 |
| US20220288195A1 (en) | 2022-09-15 |
| IL290924A (en) | 2022-04-01 |
| EP4021923A1 (en) | 2022-07-06 |
| MX2022002270A (es) | 2022-03-22 |
| CN114729010B (zh) | 2025-02-28 |
| CA3149415A1 (en) | 2021-03-11 |
| WO2021045969A1 (en) | 2021-03-11 |
| KR20220090497A (ko) | 2022-06-29 |
| JP7635208B2 (ja) | 2025-02-25 |
| PH12022550490A1 (en) | 2023-02-06 |
| CN114729010A (zh) | 2022-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091513A1 (ru) | Вакцины против вируса гепатита b (hbv) и их применение | |
| CY1122790T1 (el) | Αντι-ανθρωπινου ιου των θηλωματων 16 ε7 τ κυτταρου υποδοχεις | |
| CO2019003675A2 (es) | Meganucleasas diseñadas especificamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b. | |
| EA202000369A1 (ru) | ЭКСПРЕССИОННЫЙ ВЕКТОР ДЛЯ СОЗДАНИЯ ИММУНОБИОЛОГИЧЕСКОГО СРЕДСТВА ДЛЯ ИНДУКЦИИ СПЕЦИФИЧЕСКОГО ИММУНИТЕТА ПРОТИВ ВИРУСА ТЯЖЕЛОГО ОСТРОГО РЕСПИРАТОРНОГО СИНДРОМА SARS-CoV-2 (ВАРИАНТЫ) | |
| PH12020550924A1 (en) | Heptatitis b virus (hbv) vaccines and uses thereof | |
| UY30385A1 (es) | Vacuna recombinante contra el virus de la lengua azul | |
| PH12018502684B1 (en) | A rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate | |
| RU2018130813A (ru) | Вакцины против fmdv на основе рекомбинантного аденовирусного вектора и их применение | |
| MX391149B (es) | Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion. | |
| WO2017044895A3 (en) | MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF | |
| EA201990010A1 (ru) | Вакцина против вируса инфекционного бронхита | |
| BR112022011099A2 (pt) | Tratamento de doenças relacionadas ao vírus da hepatite b | |
| CL2017003224A1 (es) | Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante | |
| EA201690115A1 (ru) | Комбинированные иммуногенные композиции | |
| AR129904A2 (es) | Cepas de alto rendimiento del virus de la fiebre amarilla con una propagación incrementada en las células | |
| CO6541529A2 (es) | Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos | |
| BR112017019776A2 (pt) | proteínas de fusão que compreendem glicoproteínas de superfície de alfavírus modificadas e antígeno associado a tumor e métodos dos mesmos | |
| RU2015113826A (ru) | Выделение вируса, родственного парвовирусу-2 собак, от енота | |
| AR108014A1 (es) | Vacuna universal para enfermedades virales y método de vacunación | |
| AR101468A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| PH12022550490A1 (en) | Hepatitis b virus vaccines | |
| JP2023052092A (ja) | 免疫原性組成物 | |
| BR112019008584A2 (pt) | vacinas de mosaico para vírus de doença de pé-e-boca de sorotipo a | |
| DOP2014000215A (es) | Virus de la enfermedad de marek modificado y vacunas elaboradas con él | |
| WO2010135054A3 (en) | Mutations in a toll-like receptor motif in the ns4b of classical swine fever virus skin brescia influences virulence in swine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2845 DE 15-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |